Group B Streptococcus and Intraamniotic Inflammation and Infection

Area of Science:

• Obstetrics and Gynecology
• Infectious Diseases
• Neonatology

Background:

• Intraamniotic inflammation and infection occur in 2-5% of term deliveries.
• Group B Streptococcus (GBS) is a significant cause of intraamniotic infection, leading to invasive neonatal disease and maternal morbidity.

Purpose of the Study:

• To outline current recommendations for GBS screening and management during pregnancy.
• To detail antibiotic prophylaxis strategies for GBS-positive individuals and those with penicillin allergies.
• To highlight ongoing research into maternal anti-GBS vaccines.

Main Methods:

• Review of current clinical guidelines and recommendations for GBS screening and management.
• Summary of recommended antibiotic prophylaxis regimens based on penicillin allergy risk and GBS status.
• Mention of ongoing clinical trials for maternal GBS vaccines.

Main Results:

• Universal GBS screening via vaginal-rectal swabs is recommended between 36-37 weeks gestation.
• Intrapartum antibiotic prophylaxis is advised for GBS-positive individuals and those with risk factors.
• Penicillin is the primary choice for prophylaxis; alternatives include cefazolin, clindamycin, or vancomycin for penicillin-allergic individuals.

Conclusions:

• Effective screening and intrapartum antibiotic prophylaxis strategies are crucial for reducing GBS-related neonatal and maternal complications.
• Personalized antibiotic selection is necessary for patients with penicillin allergies.
• Maternal vaccination represents a promising future strategy for GBS prevention.